All In Biotech

Drug Trial Radar · NCT06251024

Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older

A Phase IIb, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an RSV Vaccine Candidate in Adult Participants 60 Years and Older

Last checked: Nov 20, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 4,541 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,541

Actual

Start

Apr 2, 2024

Primary completion

Mar 11, 2025

Study completion Mar 11, 2025

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Feb 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this Phase IIb study is to evaluate the efficacy of the RSV vaccine candidate for the prevention of lower respiratory tract disease (LRTD) due to RSV. The study will enroll approximately 4500 adults aged 60 years and older in a 1:1 ratio to receive a single intra-muscular (IM) administration of either a pre-determined dose of the RSV vaccine candidate or placebo.

Conditions

  • Respiratory Syncytial Virus Infection
  • Healthy Volunteers

Interventions

  • RSV vaccine candidateBiological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

  • PlaceboBiological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Presence of the first episode of RSV-LRTD (RSV A and/or RSV B) ≥ 14 days after vaccinationTime frame: ≥ 14 days after vaccination

Locations

25 sites in 6 countries. Site status is shown where the registry gives one.

  • Investigational Site Number : 0360005

    Norwood, Australia

  • Investigational Site Number : 0360003

    Botany, New South Wales, Australia

  • Investigational Site Number : 0360004

    Sippy Downs, Queensland, Australia

  • Investigational Site Number : 0360001

    Southport, Queensland, Australia

  • Investigational Site Number : 0360002

    Camberwell, Victoria, Australia

  • Investigational Site Number : 1520002

    Santiago, Chile

  • Investigational Site Number : 1520008

    Santiago, Chile

  • Investigational Site Number : 1520006

    Concepción, Biobio, Chile

  • Investigational Site Number : 1520005

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520004

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1700004

    Aguazul, Colombia

  • Investigational Site Number : 1700002

    Barranquilla, Colombia

  • Investigational Site Number : 1700006

    Bogotá, Colombia

  • Investigational Site Number : 1700007

    Cali, Colombia

  • Investigational Site Number : 1700003

    Girardot, Colombia

  • Investigational Site Number : 1700005

    Ibague, Colombia

  • Investigational Site Number : 1700001

    Quindío, Colombia

  • Investigational Site Number : 2140001

    Santo Domingo, Dominican Republic

  • Investigational Site Number : 2140002

    Santo Domingo, Dominican Republic

  • Investigational Site Number : 3400001

    San Pedro Sula, Honduras

  • Investigational Site Number : 3400003

    Tegucigalpa, Honduras

  • Investigational Site Number : 3400002

    Tegucugalpa, Honduras

  • Investigational Site Number : 4840003

    Querétaro, Mexico

  • Investigational Site Number : 4840002

    León, Guanajuato, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.